NASDAQ: AVTXAvalo Therapeutics Inc Stock
$7.54-0.04 (-0.53%)
Updated Jan 24, 2025
AVTX Price
$7.54
Fair Value Price
$19.71
Market Cap
$78.37M
52 Week Low
$4.01
52 Week High
$34.46
P/E
-0.39x
P/B
3.72x
P/S
11.98x
PEG
N/A
Dividend Yield
N/A
Revenue
$820.00k
Earnings
-$7.96M
Gross Margin
182%
Operating Margin
-1,225.73%
Profit Margin
-970.5%
Debt to Equity
3.59
Operating Cash Flow
-$37M
Beta
1.12
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AVTX Overview
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AVTX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Value
A
Growth
C
Momentum
D
Sentiment
F
Safety
D
Financials
F
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AVTX
Ranked#301 of 555
Ranked#301 of 555
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.17 | A | |
| $122.04 | A | |
| $2.96 | A |
Be the first to know about important AVTX news, forecast changes, insider trades & much more!
AVTX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AVTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVTX ($7.54) is undervalued by 61.75% relative to our estimate of its Fair Value price of $19.71 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AVTX ($7.54) is significantly undervalued by 61.75% relative to our estimate of its Fair Value price of $19.71 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AVTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AVTX due diligence checks available for Premium users.
Valuation
AVTX fair value
Fair Value of AVTX stock based on Discounted Cash Flow (DCF)
Price
$7.54
Fair Value
$19.71
Undervalued by
61.75%
AVTX ($7.54) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AVTX ($7.54) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AVTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AVTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.39x
Industry
-188.16x
Market
30.33x
AVTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.72x
Industry
5.04x
AVTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AVTX's financial health
Profit margin
Revenue
$249.0k
Net Income
$23.0M
Profit Margin
9,251.8%
AVTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AVTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$98.5M
Liabilities
$75.7M
Debt to equity
3.59
AVTX's short-term assets ($86.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVTX's short-term assets ($86.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AVTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.5M
Investing
$0.0
Financing
$0.0
AVTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AVTX vs Biotech Stocks
Avalo Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.